Avegen: scaling personalised care through adaptable digital health solutions

Avegen, a health technology company founded in 2015, aims to address critical gaps in patient care and engagement using scalable digital tools. The company developed the HealthMachine platform to empower healthcare providers and patients with data-driven, personalised care solutions. The clinician dashboard and accompanying patient facing app helps healthcare providers to manage patient journeys, improve outcomes and scale programmes across conditions like maternal health, cardiovascular care and chronic diseases.

Creating the building blocks for personalised care solutions

Avegen’s solutions have been used globally across areas like maternal health, cardiovascular care and chronic disease management. Through iterative development and partnerships with health systems, NGOs and pharmaceutical companies, Avegen evolved HealthMachine into a modular, patient-centric platform with a strong foundation in clinical evidence and user experience design.

HealthMachine addresses fragmented, episodic care experienced by patients with long term conditions in the outpatient environment. It helps to extend care beyond hospital settings, delivering continuous, personalised support that aligns with the shift of hospital to community care.

The dashboard is made up of fully customisable building blocks, providing the basis for tailored solutions that are co-designed with secondary care providers. In this way, HealthMachine respond directly to the site, its clinicians and patients.

In 2023, Avegen launched HealthMachine 2.0, a more powerful and flexible platform that accelerates the development and scaling of digital health solutions across a range of long-term conditions and care settings.

Enhancing the HIV outpatient pathway at Chelsea and Westminster Hospital

Driving growth with evaluation

Integrating evaluation into the development of HealthMachine has been critical to ensuring the platform delivers measurable, patient-centred impact. Continuous evaluation has allowed for iterative improvements, alignment with clinical goals and robust evidence of effectiveness.

In the cardiac rehabilitation programme at Wycombe Hospital, for example, HealthMachine enabled earlier patient onboarding and improved remote engagement. Beat Better – developed through a collaboration between Avegen and Bucks, Oxford and West Berkshire Integrated Care Board (BOB-ICB) – lead to increased completion rates and better adherence to post-discharge care plans.

These insights help to validate the platform’s ability to enhance operational efficiency, improve patient outcomes and support scalable models of long-term condition management – underscoring the value of embedded evaluation in shaping effective digital health interventions.

Avegen’s Accelerator journey: strengthening partnerships and validating innovation in real-world settings

Avegen joined the DigitalHealth.London Accelerator to deepen their engagement with the NHS, validate HealthMachine in real-world settings and scale their impact on long-term condition management.

The programme met expectations – providing access to NHS stakeholders, guidance on procurement and strategic mentoring that helped refine their value proposition. With the Accelerator team’s support, Avegen strengthened their existing relationships and widened their network of NHS partners.

As a founder, the programme offered insights into NHS priorities and accelerated our ability to navigate complex health systems. It also reinforced the importance of co-design, evaluation and alignment with national digital and prevention agendas.

We would strongly recommend the Accelerator to other healthtech innovators. It’s a unique platform for building meaningful NHS relationships, testing innovations in practice and driving sustainable growth. The experience has been a milestone in our journey to improve patient outcomes through scalable, evidence-based digital solutions.

What’s next for Avegen?

Avegen’s next aim for HealthMachine is to expand partnerships with NHS trusts and increase its use across varied long-term conditions. They plan to achieve this through partnering with new clinical teams; targeted user testing; refining the platform based on clinician and patient feedback; and demonstrating cost-effective outcomes.

Avegen invites healthcare leaders and investors to get in touch if they are interested in collaborating to support sustainable, community-based long-term condition management.

Learn more about Avegen by visiting their website and connecting on LinkedIn.

Avegen is part of cohort 8 of the DigitalHealth.London Accelerator programme.

The DigitalHealth.London Accelerator programme is funded by the UK Government via the UK Shared Prosperity Fund (UKSPF). It is delivered by the Health Innovation Network (HIN) South London in partnership with the Office of Life Sciences, CW+, Medicity, NHS England, the Mayor of London and the Levelling Up Fund.

For more information, please visit https://www.gov.uk/government/publications/uk-
shared-prosperity-fund-prospectus.